Oncology

Telomeres on chromosomes
#DNA #Lung cancer #MAIA Biotechnology #Oncology #Phase II trial

Positive efficacy updates for Phase II trial in non-small cell lung cancer

MAIA Biotechnology has shared positive updated data from its THIO-101 Phase II clinical trial evaluating its lead candidate, THIO, in patients with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care therapy regimens.  In the trial, THIO was sequenced with Regeneron’s immune checkpoint inhibitor… Read More

#Cancer Research #News

#Cancer therapeutics #Cancer vaccine #CAR-T #Oncology #Radiopharmaceuticals

This week in drug discovery (3-7 February) 

News round-up for 3-7 February by DDW Senior Digital Content Editor Diana Spencer. Following World Cancer Day on 4 February, the news round-up this week focuses on new approaches to the treatment of cancer, including radiopharmaceuticals, programmable cell depletion and preventative vaccines. The top stories:… Read More

#News

Small cell lung cancer
#Ariceum Therapeutics #FDA #Lung cancer #Oncology #Orphan drugs #Radiopharmaceuticals

Radiopharmaceutical cancer therapy granted orphan drug status

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Ariceum Therapeutics’ 225Ac-SSO110 (satoreotide) for the treatment of patients with small cell lung cancer (SCLC).  Ariceum has announced plans to commence Phase I/II human clinical development of 225Ac-satoreotide under the trial name, SANTANA-225… Read More

#News #Regulatory

#Antibody drug conjugate (ADC) #Cancer therapeutics #Cancer treatment #Interview #Oncology

Reducing cancer side effects through targeted therapies

Harry Palmer, Royal Commission of 1851 Industrial Fellow and PhD at University of Strathclyde, shares with DDW’s Megan Thomas how antibody-drug conjugates (ADCs) are revolutionising cancer treatment by offering targeted therapies with improved efficacy and reduced side effects, while addressing challenges in their development and paving the way for future… Read More

#Cancer Research #Exclusive Content

RNA strand
#Akribion Therapeutics #Oncology #RNA #Seed funding #Start-ups

€8m financing to pioneer RNA-guided cell depletion 

Akribion Therapeutics has exited stealth mode and completed a seed financing round, raising €8 million to accelerate the development of novel therapeutics.  The round was led by CARMA FUND and RV Invest, with investments from MP Beteiligungs, Hessen Kapital I, Bruker Invest and High-Tech Gründerfonds. … Read More

#Business & Investment #Cancer Research #News #Start-up Zone

Vaccine vial and syringe
#Cancer vaccine #GSK #Immuno-oncology #Oncology #University of Oxford

Oxford and GSK launch £50m cancer vaccines programme

GSK and the University of Oxford will invest up to £50 ($62) million to advance the understanding of how cancer develops, which could inform the future development of vaccines.  The agreement establishes the GSK-Oxford Cancer Immuno-Prevention Programme, which unites expertise from four departments across the University and… Read More

#Business & Investment #Cancer Research #News

The tumour microenvironment
#Chemotherapy-resistance #Drug resistance #Oncology #The Institute of Cancer Research #Tumour microenvironment (TME)

Study reveals role of the secretome in cancer drug resistance

A new study has shown that non-cancerous cells positioned close to tumours can affect how cancer responds to treatment.   The researchers say factoring in the effects of these cells could improve drug development and provide new insights into the most effective use of existing cancer medications. … Read More

#Cancer Research #Editor's Choice #News

Cancer cell
#Cancer research #Cancer therapeutics #Oncology #World Cancer Day

World Cancer Day: Five key cancer drug discoveries of the year so far

For World Cancer Day, Diana Spencer collates five most significant oncology research advances so far in 2025. An AI drug discovery breakthrough Results of an in vivo mouse colorectal cancer model study have shown a 60% life extension for Oxford Drug Design’s first-in-class approach against multiple… Read More

#Cancer Research #News #Trending News

Nasdaq stock market
#Ascentage Pharma #Haematology #Market reporting #Oncology

Hong Kong based Ascentage Pharma lists on Nasdaq

Ascentage Pharma has listed on the Nasdaq Global Market, becoming the first 18A company to achieve a dual listing on the US stock market.   Ascentage Pharma offered 7,325,000 American depositary shares (ADS) at $17.25 per ADS. The proceeds from the offering are expected to be approximately $126.4… Read More

#Business & Investment #News

CAR-T therapy for leukaemia
#CAR-T #Cell therapy #FDA #Haematology #March Biosciences #Oncology

FDA Orphan Drug Designation for CD5 CAR-T cell therapy

The US Food and Drug Administration (FDA) has granted orphan drug designation to MB-105, March Biosciences’ CD5-targeted CAR-T cell therapy for the treatment of relapsed/refractory CD5-positive T-cell lymphoma (TCL).  MB-105 is in development as a treatment for TCL, T-cell acute lymphoblastic leukaemia (T-ALL), chronic lymphocytic leukaemia (CLL),… Read More

#News #Regulatory

Soft tissue sarcoma
#Oncology #Phase II trial #Sarcoma #Vyome Therapeutics

Topical gel could be a breakthrough in cancer wounds

Vyome Therapeutics has shared interim results from its Phase II proof of concept study of VT-1953 topical gel in people with malignant fungating wounds (MFW).  VT-1953, which exerts an immuno-anti-inflammatory effect by targeting TLR-MD2 and DNA gyrase, met its primary endpoint in this interim analysis, with patients… Read More

#Cancer Research #News

Quantum computer
#Artificial intelligence (AI) #Insilico Medicine #Oncology #Quantum computing

Quantum computing approach targets ‘undruggable’ protein

A study co-led by University of Toronto (U of T) researchers and Insilico Medicine has demonstrated the potential of quantum computing and artificial intelligence (AI) to transform the drug discovery pipeline.  “It’s an exciting time to be working at the interface of chemistry, quantum computing and AI. Read More

#Cancer Research #News #Trending News

Close up of vaccine syringe
#Cancer vaccine #HPV #Immunology / Virology & Vaccines #Oncology #Phase II trial #Women's health

Therapeutic HPV vaccine could eliminate precancerous cervical lesions

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).  Dr Refika Yigit, principal investigator and Oncological Gynaecologist at University… Read More

#Cancer Research #News

#Antibody drug conjugate (ADC) #Bispecific Antibodies #Breast cancer #Oncology #Solid tumours

This week in drug discovery (20-24 January) 

News round-up for 20-24 January by DDW Senior Digital Content Editor Diana Spencer. In the same week that Phesi revealed that breast cancer is the most studied disease for the fourth year in a row, there have been a number of breakthroughs in the treatment of solid tumours,… Read More

#News

The European Medicines Agency in Amsterdam
#European Commission #Monoclonal antibodies #Myeloma #Oncology #Sanofi

EU extends Sarclisa use to newly diagnosed multiple myeloma

Following the adoption of a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has now approved Sanofi’s monoclonal antibody Sarclisa (isatuximab).  It is approved in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the… Read More

#News #Regulatory